Amicus Therapeutics, Inc. (FOLD) Misses Q3 EPS by 7c

Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported Q3 EPS of ($0.31), $0.07 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $8.82 million.

For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• General Mills (GIS) Tops Q1 EPS by 3c
• UBS Upgrades Bajaj Finance Ltd. (BAF:IN) to Neutral